ArticleClinical kidney journal2020
Renal outcomes of radioligand therapy: experience of
Article in Clinical kidney journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Joint EANM/SNMMI procedure guideline for the use ofEuropean journal of nuclear medicine and molecular imaging · 2023Guideline
- Pooled it
- Safety of PSMA-Targeted Molecular Radioligand Therapy withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Dosimetry of [EJNMMI research · 2026Article
- Focusing on Prostate-Specific Membrane Antigen in Precision Diagnosis and Treatment of Prostate Cancer.Biomedicines · 2026Review
- JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging.European journal of nuclear medicine and molecular imaging · 2025Article
- Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancer management and research · 2025Review
- Design ofAnnals of translational medicine · 2024Review
- [Theranostics · 2024Article
- Extended therapy with [European journal of nuclear medicine and molecular imaging · 2023Article
- [Pharmaceuticals (Basel, Switzerland) · 2022Review
- Advances inPharmaceutics · 2022Review
- Pretherapeutic Comparative Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [Cancers · 2022Article
- Nephrotoxicity after radionuclide therapies.Translational oncology · 2022Article
- Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer.Frontiers in cell and developmental biology · 2022Review
- Impact of the molar activity and PSMA expression level on [Scientific reports · 2021Article
- Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer.Current oncology (Toronto, Ont.) · 2021Article
- Renal Safety of [Cancers · 2021Article
- Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.Targeted oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadioligand therapy (RLT) with
methodsIn this retrospective cohort study, we assessed 195 men with progressive mCRPC who had received therapy with
resultsOf 195 assessed men with mCRPC, 110 patients aged [mean ± SD (range)] 70 ± 8 (53-92) years were recruited into this study with median follow-up of 8 (interquartile range 5-12, minimum 3, maximum 29) months and mean baseline eGFR 81 ± 13 mL/min/1.73 m
conclusionsCurrent Lu-PSMA RLT protocols appear to carry a mild nephrotoxic risk with the rate of about 4.5%. Prior CKD is potentially the most significant risk factor of post-RLT renal dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.